Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.
Clin Infect Dis
; 67(5): 791-794, 2018 08 16.
Article
em En
| MEDLINE
| ID: mdl-29933437
ABSTRACT
Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
HIV-1
/
Inibidores de Integrase de HIV
/
Integrases
/
Farmacorresistência Viral
/
Compostos Heterocíclicos com 3 Anéis
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Infect Dis
Assunto da revista:
DOENCAS TRANSMISSIVEIS
Ano de publicação:
2018
Tipo de documento:
Article